Role of 5-HT receptors in treatment of overactive bladder

Drugs of Today

Volumn 39, Issue 8, 2003, Pages 599-607

  Khaled, Sabri M ^a   Elhilali, Mostafa M ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 [2 (METHANESULFONAMIDO)ETHYL] 4 PIPERIDINYL] 1 PROPANONE; 1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; DOXAZOSIN; DULOXETINE; METHYSERGIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN UPTAKE INHIBITOR; ONDANSETRON; OXYBUTYNIN; PROPANTHELINE BROMIDE; PROPIVERINE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TOLTERODINE; ZATOSETRON;

BLADDER CONTRACTION; BLADDER FUNCTION; BLADDER SPHINCTER; CAT; DETRUSOR MUSCLE; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; FOREBRAIN; HEART RATE; HUMAN; HYPERTENSION; MICTURITION; NAUSEA; NERVE CONDUCTION; NONHUMAN; OVERACTIVE BLADDER; PONS; RAT; REVIEW; SENSORY NERVE; SEROTONINERGIC NERVE; SEROTONINERGIC SYSTEM; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SPINAL CORD; STRESS INCONTINENCE; SYMPATHETIC REFLEX; URINE INCONTINENCE; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANIMALS; CLINICAL TRIALS; HUMANS; RECEPTORS, SEROTONIN; REFLEX; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE;

EID: 0142120171     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.8.799407     Document Type: Review

References (60)

1. Milsom, I., Abrams, P., Cardozo, L. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001, 87: 760-6.
2. Stewart, W., Herzog, R., Wein, A. et al. Prevalence and impact of overactive bladder in the US: Results from the NOBLE program. Presented at the International Continence Society, Seoul, Korea, September 2001.
3. Ferguson, D., Christopher, N. Urinary bladder function and drug development. Trends Pharmacol Sci 1996, 17: 161-5.
4. De Groat, W.C., Booth, A.M., Yoshimura, N. Neurophysiology of micturition and its modification in animal models of human disease. En: Maggi, C.A. (Ed.). Nervous Control of the Urogenital System. Harwood Academic Publishers, Chur, Switzerland 1993, 227-90.
5. Thüroff, J.W., Bunke, B., Ebner, A. et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin versus propantheline versus placebo. J Urol 1991, 145: 813-6.
6. Gleason, D.M., Susset, J., White, C. et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999, 54: 420-3.
7. Fantl, J.A., Newman, D.K., Colling, J. Urinary incontinence in adults: Acute and chronic management. Clinical Practice Guideline. United States Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, Rockville, Maryland No. 2, 1996.
8. Thompson, I.M., Lauvetz, R. Oxybutynin in bladder spasm, neurogenic bladder, and enuresis. Urology 1976, 8: 452-4.
9. Yarker, Y.E., Goa, K.L., Fitton, A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995, 6: 243-62.
10. Anderson, R.U., Mobley, D., Blank, B. et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999, 161: 1809-12.
11. Birns, J., Lukkari, E., Malone-Lee, J.G. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int 2000, 85: 793-8.
12. Versi, E., Appell, R., Mobley, D. et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 2000, 95: 718-21.
13. Nilvebrant, L., Hallen, B., Larsson, G. Tolterodine - A new bladder selective muscarinic receptor antagonist: Preclinical, pharmacological and clinical data. Life Sci 1997, 60: 1129-36.
14. Drutz, H.P., Appell, R.A., Gleason, D., Klimberg, I., Radomski, S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999, 10: 283-9.
15. Appell, R.A. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997, 50: 90-6.
16. Jonas, U., Hofner, K., Madersbacher, H. et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge in continence, and urgency: Urodynamic evaluation. The International Study Group. World J Urol 1997, 15: 144-51.
17. Madersbacher, H., Halaska, M., Voigt, R. et al. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999, 84: 646-51.
18. Dahlström, A., Fuxe, K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brainstem neurons. Acta Physiol Scand 1964, 62 (Suppl. 232): 5-55.
19. Dahlström, A., Fuxe, K. Evidence for the existence of monoamine neurons in the central nervous system. II. Experimentally induced changes in the intraneuronal amine levels of bulbospinal neuron systems. Acta Physiol Scand 1965, 64 (Suppl. 247): 7-85.
20. Sharma, A., Goldberg, M.J., Cerimele, B.J. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000, 40: 161-7.
21. Thor, K.B., Katofiasc, M.A. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995, 274: 1014-24.
22. Nadelhaft, I., Vera, P.L. Central nervous system neurons infected by pseudorabies virus injected into the rat urinary bladder following unilateral transection of the pelvic nerve. J Comp Neurol 1995, 359: 443-56.
23. Sugaya, K., Roppolo, J.R., Yoshimura, N. et al. The central neural pathways involved in micturition in the neonatal rats as revealed by the injection of pseudorabies virus into the bladder. Neurosci Lett 1997, 223: 197-200.
24. Vizzard, M.A., Erickson, V.L., Card, J.P. et al. Transneuronal labeling of neurons in the adult rat brain and spinal cord after injection of pseudorabies virus into the urethra. J Comp Neurol 1997, 355: 629-40.
25. Marson, L. Identification of central nervous system neurons that innervate the bladder body, bladder base, or external urethral sphincter of female rats: A transneuronal tracing study using pseudorabies virus. J Comp Neurol 1997, 389: 584-602.
26. Gerhardt, C.C., van Heerikhuizen, H. Functional characteristics of heterologously expressed 5-HT receptors. Eur J Pharmacol 1997, 334: 1-23.
27. Hoyer, D., Clarke, D.E., Fozard, J.R. et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994, 46: 157-203.
28. Thor, K.B., Nickolaus, S., Helke, C. J. Autoradiographic localization of 5-hydroxytryptamine1A, 5-hydroxytryptamine1B and 5-hydroxytryptamine1C/2 binding sites in the rat spinal cord. Neuroscience 1993, 55: 235-52.
29. Bockaert, J., Fozard, J.R., Durmuis, A. et al. The 5-HT4 receptor: A place in the sun. Trends Pharmacol Sci 1992, 13: 141-5.
30. Helton, L., Thor, K.B., Baez, M. 5-Hydroxytryptamine2A, 5-hydroxytryptamine 2B, and 5-hydroxytryptamine2C receptor mRNA expression in the spinal cord of rat, cat, monkey, and human. Neuroreport 1995, 5: 2617-20.
31. Lumb, B.M. Brainstem control of visceral afferent pathways in the spinal cord. Prog Brain Res 1986, 67: 279-93.
32. Oh, U.T., Hobbs, S.F., Garrison, D. et al. Responses of raphe-spinal neurons (RSN) to urinary bladder distension (UBD) and sympathetic nerve stimulation. Abstr Soc Neurosci 1986, 12: 375.
33. Espy, M.J., Downie, J.W., Fine, A. Effect of 5-HT receptor and adrenoceptor antagonists on micturition in conscious cats. Eur J Pharmacol 1992, 221: 167-70.
34. De Groat, W.C., Booth, A.M., Krier, J. et al. Neural control of the urinary bladder and large intestine. In: Brooks, C.M., Koizumi, K., Sato, A. (Eds.). Integrative Functions of the Autonomic Nervous System. University of Tokyo Press, Tokyo 1979, 50-67.
35. McMahon, S.B., Spillane, K. Brain stem influences on the parasympathetic supply to the urinary bladder of the cat. Brain Res 1982, 234: 237-49.
36. Morrison, J.F.B., Spillane, K. Neuropharmacological studies on descending inhibitory controls over the micturition reflex. J Auton Nerv Syst 1986, (Suppl.): 393-7.
37. Espy, M.J., Downie, J.W. Serotonergic modulation of cat bladder function before and after spinal cord transection. Eur J Pharmacol 1995, 287: 173-7.
38. Thor, K.B., Katofiasc, M.A., Danuser, H. et al. The role of 5-HT1A receptors in control of lower urinary tract function in cats. Brain Res 2002, 946: 290-7.
39. Katofiasc, M.A., Nissen, J., Audia, A.J., Thor, K.B. Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci 2002, 71: 1227-36.
40. Lecci, A., Giuliani, S., Santicioli, P. et al. Involvement of 5-HT1A receptors in the modulation of micturition reflexes in the anesthetized rat. J Pharmacol Exp Ther 1992, 262: 181-9.
41. Testa, R.L., Guarneri, E., Poggesi, P. et al. Effects of several 5-hydroxytryptamine1A receptor ligands on the micturition reflex in rats: Comparison with WAY 100635. J Pharmacol Exp Ther 1999, 290: 1258-69.
42. Kakizaki, H., Yoshiyama, M., Koyanagi, T. et al. Effect of WAY100635, a selective 5-HT1A-receptor antagonist on the micturition-reflex pathway in the rat. Am J Physiol 2001, 280: R1407-13.
43. Conley, R.K., Williams, J.T., Ford, A.P.D.W. et al. The role of α1-adrenoceptors and 5-HT1A in the control of the micturition reflex in male anesthetized rats. Br J Pharmacol 2001, 133: 61-72.
44. Testa, R., Guarneri, L., Angelico, P. et al. Effect of different 5-hydroxytryptamine receptor subtype antagonists on the micturition reflex in rats. BJU Int 2001, 87: 256-64.
45. Ishizuka, O., Gu, B., Igawa, Y. et al. Role of supraspinal serotonin receptors for micturition in normal conscious rats. Neurourol Urodyn 2002, 21: 225-30.
46. Maggi, C.A., Borsini, F., Lecci, A. et al. The effect of acute or chronic administration of imipramine on spinal and supraspinal micturition reflexes in rats. J Pharmacol Exp Ther 1989, 248: 278-85.
47. Kodama, M., Takimoto, Y. Influence of 5-hydroxytryptamine and the effect of a new serotonin receptor antagonist (sarpogrelate) on detrusor smooth muscle of streptozotocin-induced diabetes mellitus in the rat. Int J Urol 2000, 7: 231-5.
48. Leonardi, A., Guarneri, L., Poggesi, E. et al. N-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-nitrophenyl) Cyclohexanecarboxamide: A novel pre- and postsynaptic 5-hydroxytryptamine 1α receptor antagonist active on the lower urinary tract. J Pharmacol Exp Ther 2001, 299: 1027-37.
49. Forster, E.A., Cliffe, I.A., Bill, D.J. et al. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol 1995, 25: 81-8.
50. Johansson, L., Sohn, D., Thorberg, S.O. et al. The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299. J Pharmacol Exp Ther 1997, 283: 216-25.
51. Pehrson, R., Ojteg, G., Ishizuka, O. et al. Effects of NAD-299, a new, highly selective 5-HT(1A) receptor antagonist, on bladder function in rats. Naunyn Schmiedebergs Arch Pharmacol 2002, 366: 528-36.
52. Khan, M.A., Dashwood, M.R., Thompson, C.S. et al. Time-dependent up-regulation of neuronal 5-hydroxytryptamine binding sites in the detrusor of a rabbit model of partial bladder outlet obstruction. World J Urol 1999, 17: 255-60.
53. Khan, M.A., Thompson, C.S., Dashwood, M.R. et al. Doxazosin modifies serotonin-mediated rabbit urinary bladder contraction. Potential clinical relevance. Urol Res 2000, 28: 116-21.
54. Hills, J., Meldrum, L.A., Klarskov, P. et al. A novel nonadrenergic, non-cholinergic nerve-mediated relaxation of the pig bladder neck: An examination of possible neurotransmitter candidates. Eur J Pharmacol 1984, 99: 287-93.
55. Sellers, D.J., Chess-Williams, R., Chapple, C.R. 5-Hydroxytryptamine-induced potentiation of cholinergic responses to electrical field stimulation in pig detrusor muscle. BJU Int 2000, 86: 714-8.
56. Ishigooka, J., Nagata, E., Takahashi, A. et al. Simultaneous monitoring of inhibition of serotonin uptake by platelets and plasma drug concentrations following administration of duloxetine, a new antidepressant candidate, to healthy volunteers. Current Ther Res 1997, 10: 679-92.
57. Turcotte, J.E., Debonnel, G., de Montigny, C. et al. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 2001, 24: 511-21.
58. Sharma, A., Goldberg, M.J., Cerimele, B.J. et al. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000, 40: 161-7.
59. Zinner, N., Thor, K.B., Yalcin, I. et al. Efficacy and safety of duloxetine in stress urinary incontinent patients. Proceedings of the 19th Annual Meeting of Urodynamics Society, San Diego: The Society, San Diego, Calif. 1998.
60. Norton, P.A., Zinner, N.R., Yalcin, I. et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002, 187: 40-8.